TW200621748A - Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines - Google Patents

Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines

Info

Publication number
TW200621748A
TW200621748A TW094130010A TW94130010A TW200621748A TW 200621748 A TW200621748 A TW 200621748A TW 094130010 A TW094130010 A TW 094130010A TW 94130010 A TW94130010 A TW 94130010A TW 200621748 A TW200621748 A TW 200621748A
Authority
TW
Taiwan
Prior art keywords
oxoisoindolines
dioxopiperidin
substituted
preparation
processes
Prior art date
Application number
TW094130010A
Other languages
English (en)
Inventor
George W Muller
Roger Chen
Manohar Tukaram Saindane
Chuansheng Ge
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35385616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200621748(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of TW200621748A publication Critical patent/TW200621748A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
TW094130010A 2004-09-03 2005-09-02 Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines TW200621748A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60740904P 2004-09-03 2004-09-03

Publications (1)

Publication Number Publication Date
TW200621748A true TW200621748A (en) 2006-07-01

Family

ID=35385616

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094130010A TW200621748A (en) 2004-09-03 2005-09-02 Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines

Country Status (22)

Country Link
US (1) US7863451B2 (zh)
EP (2) EP1797068B1 (zh)
JP (2) JP2008512379A (zh)
KR (1) KR20070057907A (zh)
CN (1) CN101080400A (zh)
AR (1) AR050724A1 (zh)
AU (1) AU2005282728A1 (zh)
BR (1) BRPI0514865A (zh)
CA (1) CA2579291C (zh)
ES (2) ES2437592T3 (zh)
GT (1) GT200500242A (zh)
HN (1) HN2005000508A (zh)
IL (1) IL181674A0 (zh)
MX (1) MX2007002521A (zh)
NZ (1) NZ554068A (zh)
PA (1) PA8643901A1 (zh)
PE (1) PE20060648A1 (zh)
SV (1) SV2007002219A (zh)
TW (1) TW200621748A (zh)
UY (1) UY29097A1 (zh)
WO (1) WO2006028964A1 (zh)
ZA (1) ZA200702382B (zh)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
SI1907373T1 (sl) 2005-06-30 2013-03-29 Celgene Corporation Postopki za pripravo 4-amino-2-(2.6-dioksopiperidin-3-il)izoindolin-1,3-dionskih spojin
CN101186611B (zh) * 2006-11-15 2011-05-18 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的吡咯啉-2-酮衍生物及其制备和应用
JP2011513497A (ja) * 2008-03-11 2011-04-28 ドクター・レディーズ・ラボラトリーズ・リミテッド レナリドミドの調製
DE102008057284A1 (de) 2008-11-14 2010-05-20 Ratiopharm Gmbh Tabletten enthaltend Lenalidomid und Adhäsionsverstärker
DE102008057285A1 (de) 2008-11-14 2010-05-20 Ratiopharm Gmbh 3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidindion in Form einer festen Lösung
DE102008057335A1 (de) 2008-11-14 2010-05-20 Ratiopharm Gmbh Amorphes Lenalidomid
AU2009314512B2 (en) * 2008-11-17 2013-04-04 Dr. Reddy's Laboratories Ltd. Lenalidomide solvates and processes
WO2010093434A1 (en) 2009-02-11 2010-08-19 Celgene Corporation Isotopologues of lenalidomide
AU2010220204B2 (en) 2009-03-02 2015-10-08 Generics [Uk] Limited Improved process
CN101580501B (zh) * 2009-06-01 2011-03-09 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮的合成方法及其中间体
MX2012001890A (es) * 2009-08-12 2012-03-26 Synthon Bv Sales de lenalidomida.
EP2477973B1 (en) * 2009-09-16 2014-08-27 Ranbaxy Laboratories Limited Process for the preparation of a crystalline form of lenalidomide
TWI475014B (zh) * 2009-09-17 2015-03-01 Scinopharm Taiwan Ltd 固體形態的３－（４－胺基－１－側氧基－１，３－二氫－異吲哚－２－基）－哌啶－２，６－二酮及其製造方法
WO2011050962A1 (en) 2009-10-29 2011-05-05 Ratiopharm Gmbh Acid addition salts of lenalidomide
CN101696205B (zh) 2009-11-02 2011-10-19 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
CN102127054B (zh) * 2009-11-02 2013-04-03 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
CN102060842B (zh) * 2009-11-02 2013-05-08 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
WO2011069608A1 (en) * 2009-12-09 2011-06-16 Ratiopharm Gmbh S-lenalidomide, polymorphic forms thereof and blend comprising s- und r-lenalidomide
CN101817813B (zh) * 2010-01-15 2013-04-10 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮晶体ⅳ及其药用组合物
RS56232B1 (sr) 2010-02-11 2017-11-30 Celgene Corp Derivati arilmetoksi izoindolina i kompozicije koje ih obuhvataju i postupci njihove primene
CN102453021A (zh) * 2010-10-22 2012-05-16 重庆医药工业研究院有限责任公司 来那度胺的新晶型及其制备方法
WO2012079075A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
US9540341B2 (en) 2011-07-19 2017-01-10 Amplio Pharma, Llc Crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
EP2877462B1 (en) * 2012-07-27 2019-09-04 Celgene Corporation Processes for preparing isoindoline-1,3-dione compounds
ES2914876T3 (es) * 2012-08-09 2022-06-17 Celgene Corp Procesos para la preparación de (S)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2, 6-diona y formas farmacéuticas aceptables de las mismas
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
CN103242215A (zh) * 2013-05-27 2013-08-14 合肥医工医药有限公司 一种来那度胺中间体的制备方法
WO2016024286A2 (en) 2014-08-11 2016-02-18 Avra Laboratories Pvt. Ltd. An improved process for synthesis of lenalidomide
EP3643709B1 (en) 2014-10-30 2021-10-20 Kangpu Biopharmaceuticals, Ltd. Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
CN104447689B (zh) * 2014-12-22 2016-07-20 上海迈柏医药科技有限公司 来那度胺的晶型及其制备方法
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
CN108191826A (zh) * 2018-01-08 2018-06-22 浙江省医学科学院 一种来那度胺晶体及其制备方法
EA202092248A1 (ru) 2018-04-23 2021-02-04 Селджин Корпорейшн Замещенные соединения 4-аминоизоиндолин-1,3-диона, их композиции и способы лечения ими
EP3820573B1 (en) 2018-07-10 2023-08-09 Novartis AG 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
EP3848363B1 (en) * 2018-09-07 2023-07-19 Medshine Discovery Inc. Tricyclic substituted piperidine dione compound
EP3880669A1 (en) 2018-11-13 2021-09-22 Biotheryx, Inc. Substituted isoindolinones
CN109369504B (zh) * 2018-12-06 2020-05-12 温州大学 含硫3-亚甲基异吲哚啉-1-酮衍生物的制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
DE4236880A1 (de) * 1992-10-31 1994-05-05 Basf Ag N-Phenyl substituierte Glutarimide und N-Phenylglutarsäureamide, deren Herstellung und Verwendung
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US6114355A (en) 1993-03-01 2000-09-05 D'amato; Robert Methods and compositions for inhibition of angiogenesis
US5463063A (en) 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
DE19601303A1 (de) * 1996-01-16 1997-07-17 Boehringer Ingelheim Kg Neuartige Benzoylguanidin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln
EP2305663B1 (en) * 1996-07-24 2014-12-17 Celgene Corporation Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and method of reducing TNF alpha levels
US5798368A (en) * 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
HU228769B1 (en) * 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
DE69739181D1 (de) * 1996-08-12 2009-02-05 Celgene Corp Neue immunotherapeutische Mittel und deren Verwendung in der Reduzierung von Cytokinenspiegel
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
US5874448A (en) * 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
JP4695259B2 (ja) * 1998-03-16 2011-06-08 セルジーン コーポレイション ２−（２，６−ジオキソピペリジン−３−イル）イソインドリン誘導体、その製剤および炎症性サイトカイン阻害剤としてのその使用
ATE306469T1 (de) * 1999-03-18 2005-10-15 Celgene Corp Substituierte 1-oxo- und 1,3-dioxoisoindoline und ihre verwendung in pharmazeutischen zusammensetzungen zur senkung des spiegels inflammatorisch wirkender cytokine
EP1193248A1 (en) * 2000-09-30 2002-04-03 Aventis Pharma Deutschland GmbH Malonamid and malonamic ester derivatives with antithrombotic activity, their preparation and their use
US6458810B1 (en) * 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
JP4242651B2 (ja) * 2000-11-30 2009-03-25 ザ チルドレンズ メディカル センター コーポレイション ４−アミノ−サリドマイドエナンチオマーの合成法
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
JP2002284761A (ja) * 2001-01-17 2002-10-03 Toray Ind Inc 光学活性３−アミノピロリジン−２，５−ジオン誘導体および光学活性３−アミノピロリジン誘導体の製造方法
CA2457319C (en) * 2001-08-06 2011-07-05 The Children's Medical Center Corporation Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
US7091343B2 (en) * 2002-03-15 2006-08-15 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
CH696542A5 (de) * 2003-07-09 2007-07-31 Siegfried Ltd Verfahren zur Herstellung von substituierten 2,6-Dioxopiperidin-3-yl-Verbindungen.
SI1907373T1 (sl) * 2005-06-30 2013-03-29 Celgene Corporation Postopki za pripravo 4-amino-2-(2.6-dioksopiperidin-3-il)izoindolin-1,3-dionskih spojin
ZA200802490B (en) * 2005-08-31 2009-10-28 Celgene Corp Isoindole-imide compounds and compositions comprising and methods of using the same
RU2009114159A (ru) * 2006-09-15 2010-10-20 Селджин Корпорейшн (Us) N-метиламинометилизоидольные соединения, композиции, включающие их, и способы их применения
JP2011513497A (ja) 2008-03-11 2011-04-28 ドクター・レディーズ・ラボラトリーズ・リミテッド レナリドミドの調製
WO2009111948A1 (zh) 2008-03-13 2009-09-17 天津和美生物技术有限公司 3-(4-氨基-1-氧代-1,3-二氢异吲哚-2-基)哌啶-2,6-二酮及其衍生物的盐或盐的多晶型物及其制备和应用

Also Published As

Publication number Publication date
CA2579291C (en) 2011-11-29
PE20060648A1 (es) 2006-07-14
CN101080400A (zh) 2007-11-28
NZ554068A (en) 2009-07-31
AU2005282728A1 (en) 2006-03-16
US7863451B2 (en) 2011-01-04
ES2437592T3 (es) 2014-01-13
IL181674A0 (en) 2007-07-04
SV2007002219A (es) 2007-03-20
GT200500242A (es) 2006-06-22
WO2006028964A1 (en) 2006-03-16
US20060052609A1 (en) 2006-03-09
KR20070057907A (ko) 2007-06-07
HN2005000508A (es) 2010-10-08
EP2479172A1 (en) 2012-07-25
ZA200702382B (en) 2008-08-27
PA8643901A1 (es) 2006-05-16
BRPI0514865A (pt) 2008-06-24
CA2579291A1 (en) 2006-03-16
ES2438725T3 (es) 2014-01-20
EP1797068A1 (en) 2007-06-20
JP5701824B2 (ja) 2015-04-15
AR050724A1 (es) 2006-11-15
EP1797068B1 (en) 2013-10-09
JP2012207040A (ja) 2012-10-25
EP2479172B1 (en) 2013-10-09
MX2007002521A (es) 2007-05-09
UY29097A1 (es) 2006-03-31
JP2008512379A (ja) 2008-04-24

Similar Documents

Publication Publication Date Title
TW200621748A (en) Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines
IL188330A (en) Processes for the preparation of 4-amino-2- (6,2-dioxofipridine-3-il) compounds isoindoline-1,3-dion
ATE381539T1 (de) Dipeptidylpeptidase-hemmer zur behandlung von diabetes
WO2007136640A3 (en) Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
MY141867A (en) Substituted pyrimidines useful as protein kinase inhibitors
YU84603A (sh) Novi inhibitori tirozin kinaze
NO20062136L (no) Imidazopyrazintyrosin-kinaseinhibitorer
TW200633980A (en) Pyridones useful as inhibitors of kinases
MX2009006267A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa.
WO2007022268A3 (en) Compounds and compositions as protein kinase inhibitors
WO2007022470A3 (en) Methods and compositions for treating neurological disease
WO2005000298A3 (en) 5-membered heterocycle-based p-38 inhibitors
TW200613306A (en) Imidazotriazines as protein kinase inhibitors
TW200736249A (en) Aminopyrimidines useful as kinase inhibitors
TW200716648A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
HK1096673A1 (en) Compositions useful as inhibitors of protein kinases
JO2282B1 (en) Oxazole derivatives
MX2009003763A (es) Inhibidores de metaloproteasa derivados de heterociclicos.
MXPA05010711A (es) Compuestos y composiciones novedosos como inhibidores de proteina-quinasa.
IL172942A0 (en) Pyrazoloisoquinoline derivatives as kinase inhibitors
DE602006006985D1 (de) Pyridinderivate als pkc-theta-hemmer
PL1853232T3 (pl) Trwałe postaci krystaliczne mesylanu bifeprunoksu, postaci dawkowania oraz sposoby ich stosowania
WO2009089263A3 (en) Novel compositions and methods of use
MXPA04006031A (es) Compuestos para el tratamiento de trastornos inflamatorios.
ATE367380T1 (de) Zur behandlung von zns-erkrankungen geeignete piperazinylchinolinderivate